Processa Pharmaceuticals, Inc.
PCSA · XNASCIK 1533743fmd_1XGBDJ3WHE93ZPW182FYGW77M0Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2012 to Jun 30, 2026, 57 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | – | – | – | – | 0 | 0 | – | – | – |
| Cost of revenue | – | – | – | – | – | – | – | – | – | – |
| Gross profit | 0 | – | – | – | – | – | – | – | – | – |
| Research and development | 2 | 1 | 3 | 2 | 3 | 7 | 11 | 6 | 7 | 8 |
| Selling, general and administrative | 0 | 1 | 1 | – | – | – | – | – | – | – |
| Total operating expenses | 2 | 2 | – | – | – | – | – | – | – | – |
| Operating income | (2) | (2) | (5) | (4) | (15) | (12) | (28) | (11) | (12) | (14) |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | – | – | – | – |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before taxes | (0) | (2) | (5) | (4) | (15) | (12) | (27) | (11) | (12) | (14) |
| Income tax expense | – | 0 | (1) | (1) | (1) | (1) | – | – | – | – |
| Net income from continuing operations | (2) | (2) | (4) | (3) | (14) | (11) | – | – | – | – |
| Net income | (2) | (2) | (4) | (3) | (14) | (11) | (27) | (11) | (12) | (14) |
| Net income to common shareholders | (0) | – | (4) | (4) | (19) | (11) | (27) | (11) | (12) | (14) |